Use of premedication with intravenous immune globulin in Kawasaki disease: A retrospective review

• Published in: Pediatric allergy and immunology Vol. 32; no. 4; pp. 750 - 755
• Main Authors: Liu, Elaine, Gonzalez, Jimmy, Siu, Anita
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2021
• Subjects: adverse events; Aspirin; Child; Coronary artery disease; Demography; Electronic medical records; Globulins; Heart diseases; Humans; Immunoglobulins; Immunoglobulins, Intravenous - adverse effects; Intravenous administration; intravenous immune globulin; Kawasaki disease; Mucocutaneous lymph node syndrome; Mucocutaneous Lymph Node Syndrome - drug therapy; Patients; Pediatrics; Premedication; Retrospective Studies; Vomiting; Kawasaki disease; adverse events; premedication; intravenous immune globulin
• ISSN: 0905-6157; 1399-3038
• DOI: 10.1111/pai.13432

Background Kawasaki disease (KD) is a significant febrile illness in children and is the leading cause of acquired pediatric heart disease in developed countries. Its recommended treatment is high‐dose intravenous immune globulin (IVIG) plus aspirin. However, IVIG‐related adverse events are seen frequently in this population. Premedication is commonly used to reduce this risk, but evidence supporting this practice is conflicting. Ultimately, practices vary among institutions and no standard guidelines regarding IVIG premedication currently exist. Methods Electronic medical records for pediatric patients presenting to an academic, tertiary care medical center diagnosed with KD and who received at least one dose of IVIG were reviewed for: patient demographics, treatment characteristics, premedication use, adverse events, and coronary abnormalities at discharge. Descriptive statistics were used to evaluate study findings. Results Sixty‐six patients receiving a total of 81 distinct IVIG administrations were evaluated. Most patients (64/66, 97%) were premedicated prior to infusion with 26% of patients (17/66) experiencing an IVIG‐related adverse event, totaling 25 documented adverse events. The most common events included chills and vomiting. Overall, the average duration of hospitalization was 4.37 days. Despite appropriate medication management, five patients (7.6%) developed coronary abnormalities. Conclusion Practitioners demonstrated a widespread use of premedication for IVIG. However, 26% of patients still experienced an adverse event. While premedication was not shown to have an adverse impact on patient outcomes, it also did not demonstrate a notable reduction from a historic adverse event incidence.